Not all C. acnes are the same: the subtype story that changes everything

Meet the family — a species of six

C. acnes is divided into six main phylotypes — IA1, IA2, IB, IC, II and III — nested within three broader lineages now recognised as subspecies: type I (subsp. acnes), type II (subsp. defendens) and type III (subsp. elongatum). The names of the latter two are telling: defendens, the defender, and elongatum, a health-associated lineage almost entirely absent from acne lesions.

This map was drawn incrementally — from single-gene typing to multilocus sequence typing, and, crucially for studying mixed skin communities, single-locus sequence typing (SLST), which reads one variable region yet can detect several co-existing subtypes in a single sample. Comparative genomics across hundreds of genomes confirms the picture: a large accessory gene set drives the differences between lineages, so the phylotypes occupy genuinely different ecological niches. That is exactly why the composition of the community, not its size, is what matters.

The troublemaker: what makes phylotype IA1 so problematic

If any subtype deserves the historical reputation of C. acnes, it is phylotype IA1 — the lineage most consistently enriched in acne lesions. It is the strongest biofilm builder, forming the most abundant, best-structured fortresses of self-made matrix. It produces more porphyrins — pigments that drive reactive oxygen and ignite inflammation via the NLRP3 inflammasome. And it activates the Th17 inflammatory pathway far more strongly than its health-associated cousins.

There is an honest nuance here. The CAMP factors once blamed on IA1 are in fact present across all phylotypes, and a mobile linear plasmid predicts a strain’s inflammatory potency better than its subtype label does. IA1 is best understood as the lineage that most often carries the trouble — which is why the smarter target is its biofilm and behaviour, not the label.

The proof: it is the mix that changes, not the headcount

In the foundational metagenomic study of acne patients and healthy controls, C. acnes made up roughly the same large share of skin bacteria in both groups — yet the strain populations differed sharply. The shift is stark at the clinical level: on the back of patients with severe acne, IA1 can climb to around 96% of isolates, against roughly 39% in healthy skin.

At the level of the individual pore, acne follicles are dominated almost exclusively by a single IA1 clonal complex, whereas healthy follicles hold a heterogeneous mix of subtypes. Acne, then, is a story of monoculture replacing diversity — and that matters because the immune system does not see all subtypes equally. In skin-explant studies, IA1 alone provoked far stronger inflammation than the same quantity of bacteria supplied as a balanced mixture. The other subtypes actively dampen the response; lose them, and the brakes come off.

The good ones: why phylotypes II and III are worth protecting

If IA1 is the family troublemaker, phylotypes II and III are its quiet stewards. Type II is literally named defendens — the defender — and the evidence for its protective role, while more mechanistic than interventional, is substantial and consistent. These subtypes are reliably enriched on healthy skin and depleted in lesions. They are not bystanders but active contributors to equilibrium, which makes preserving them a therapeutic objective in its own right.

The cost of collateral damage: what broad suppression does

If the protective subtypes matter, then any treatment that removes C. acnes wholesale carries a hidden cost. This is the logic problem with broad-spectrum antibiotics and antiseptics: they cannot tell friend from foe. Isotretinoin, by starving C. acnes of its lipid habitat, produces a roughly 37-fold depletion — and into the vacuum, S. aureus expands sharply.

Antibiotics add persistence and resistance: in one multi-country survey, around two-thirds of acne patients carried resistant C. acnes. Losing the acidic, C. acnes-maintained pore also favours Malassezia yeasts and gram-negative organisms, and the barrier suffers as its lipid-inducing signals disappear. The lesson is ecological: sterilising the skin is not the same as healing it.

The diversity question: is balance loss itself the problem?

Two models compete to explain acne at the microbial level — and the honest answer is that they are complementary, not rival. The first holds that the expansion of pro-inflammatory IA1 is the proximate driver. The second holds that the loss of subtype diversity is itself the trigger, regardless of which lineage fills the gap. The bridge between them is mechanistic: a balanced mixture is markedly less inflammatory than IA1 alone at identical bacterial load. Diversity is not merely a marker of health — it is functionally protective.

Where the evidence is genuinely incomplete is cause and sequence. Most studies are cross-sectional snapshots; few have followed untreated skin over time to prove diversity loss precedes the first lesion. The prudent reading: restoring and protecting diversity is a well-supported design principle, while claims that diversity loss is the sole proven first cause should be made with care.

Targeted and durable: the case for selectivity

If broad suppression is the problem, the logical alternative is selectivity: quiet the troublesome IA1 and biofilm fraction while leaving the protective subtypes — and the wider microbiome — intact. Early intervention data are promising. Extracts that selectively shift the subtype balance, and biofilm-targeting agents engineered to disrupt IA1 specifically, have reduced both inflammatory and comedonal lesions while microbiome diversity stayed measurably unchanged.

These results are encouraging but preliminary — small, often open-label studies. And one question remains genuinely open: recolonisation kinetics. No published human study yet measures how quickly IA1 returns after selective depletion, or how long a rebalanced community persists. Because the sebaceous, anaerobic pore may re-select for IA1, durable control may require pairing subtype targeting with measures that reshape the follicular habitat itself.

Beyond inflammation: why targeted removal also clears blackheads

Here lies the most important distinction of all. Antibiotics do not clear blackheads. Their action is anti-inflammatory — they target the red papules and pustules of inflammatory acne, which is why guidelines reserve them for inflammatory disease and rely on retinoids for comedones. Comedonal acne has long been the blind spot of antibacterial therapy.

The reason is the biofilm. The microcomedone is the primary site of C. acnes biofilm formation, and that biofilm acts as a biological glue, anchoring the hyperkeratotic plug inside the pore. Within it, IA1 lipases turn sebum into comedogenic fatty acids that drive the very plugging that traps them — a self-reinforcing cycle — and biofilm-embedded bacteria are dramatically more antibiotic-tolerant. Removing the biofilm, rather than merely the bacteria, is what addresses comedonal as well as inflammatory acne. The target, once again, is not the species but its behaviour.